Over the last several months, the 340B program has witnessed an increased focus on integrity and compliance.  In September, the Government Accountability Office (GAO) released a Congressionally mandated report that called on the Health Resources and Services Administration (HRSA) to conduct audits of covered entities to ensure that 340B-discounted drugs are not provided to ineligible patients. HRSA has begun conducting audits, and pharmaceutical manufacturers are also stepping up their efforts to scrutinize whether covered entities are complying with the law.

The GAO also recommended that HRSA finalize new, more specific guidance on the definition of a 340B patient and take steps to ensure pharmaceutical manufacturers are not discriminating against covered entities when restricting distribution of their drugs.  Coinciding with the report’s release, three senior members of Congress requested that HRSA inform them of what actions the agency has taken to oversee the administration and effectiveness of the program.  There are also questions being raised about whether the 340B program is a factor in drug shortages.  With elections around the corner, both supporters and detractors of the 340B program on Capitol Hill are stepping up efforts to make changes to the program.

The conference will address how 340B stakeholders are responding to this increased scrutiny and meeting other 340B program challenges.  Conference highlights include a session devoted to program integrity and audits and a panel on how a covered entity can effectively manage its 340B program while ensuring compliance with HRSA guidelines.  Whether you work for a covered entity, pharmacy, pharmaceutical manufacturer, 340B-oriented business, or government agency, there is no better way to stay informed and play a role in shaping the future of the program than to attend the conference. You will learn from all the key players involved in the program, including federal officials and representatives from 340B advocacy organizations and industry.

In addition to the emphasis on policy matters, the conference will provide you with many opportunities for hands-on, practical advice to help with program implementation. If you are a health care provider, you will learn innovative strategies to reduce costs, remain compliant and improve care. If you work for a pharmaceutical company or other pharmacy-related business, you will learn how to prepare for this increased focus on compliance and have an opportunity to network directly with current and prospective customers. There will be opportunities to participate in small breakout sessions to get the advice you need and to share ideas with others.  As there has been a significant growth in contract pharmacies, we also will be hosting breakout sessions exclusively for pharmacies and pharmacy service companies looking to contract or expand contracts with covered entities.

*Please note that registration fees increased $50, $100, $200 and $200 respectively after January 22, 2012.

**If you are unsure as to whether your institution is part of a 340B Coalition organization, please view the list of current 340B Coalition members at www.snhpa.org/public/340b_coalition.cfm.

***If you are unsure whether your organization/company is either a non-profit member of, or contracted supplier of, the 340B Prime Vendor Program, please visit www.340bpvp.com.

If you are not yet a subscriber to the Drug Discount Monitor,
subscribe today and benefit from the discounted registration fee.
More details at www.drugdiscountmonitor.com.